We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Market first

2 May 2014 By Ian Campbell, Chris Hughes

British politicians and scientists want assurances that a takeover of AstraZeneca by U.S. rival Pfizer would be in the national interest. But good UK science requires more than corporate control. A rushed dialogue with a semi-hostile bidder helps neither the target nor the nation.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)